Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

by Margaux Geier, Renaud Descourt, Romain Corre, Guillaume Léveiller, Régine Lamy, Éric Goarant, Jean‐Louis Bizec, Cyril Bernier, Gilles Quéré, Karim Amrane, Elisabeth Gaye, François Lucia, Emilie Burte, Christos Chouaid, Gilles Robinet
Published 2020-10-01

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung

by Camille Agar, MD, Margaux Geier, MD, Guillaume Léveiller, MD, Régine Lamy, MD, Jean-Louis Bizec, MD, Marie Tiercin, MD, Cyril Bernier, MD, Gilles Robinet, MD, Hervé Léna, MD, Charles Ricordel, MD, Romain Corre, MD
Published 2021-04-01

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

by Karim Amrane, Margaux Geier, Romain Corre, Hervé Léna, Guillaume Léveiller, Florence Gadby, Régine Lamy, Jean‐Louis Bizec, Eric Goarant, Gilles Robinet, Sylvie Gouva, Gilles Quere, Ronan Abgral, Ulrike Schick, Cyril Bernier, Christos Chouaid, Renaud Descourt
Published 2020-04-01